FCA
HRMY icon

FinTrust Capital Advisors’s Harmony Biosciences HRMY Stock Holding History

FinTrust Capital Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34
Closed -$1.14K – 1392
2024
Q1 		$1.14K Hold
34
– – ﹤0.01% 1154
2023
Q4 		$1.1K Sell
34
-54
-61% -$1.51K ﹤0.01% 1133
2023
Q3 		$2.88K Sell
88
-2,407
-96% -$83.6K ﹤0.01% 971
2023
Q2 		$137K Hold
2,495
– – 0.03% 308
2023
Q1 		$137K Hold
2,495
– – 0.03% 307
2022
Q4 		$137K Sell
2,495
-15,303
-86% -$841K 0.03% 306
2022
Q3 		$911K Buy
17,798
+34
+0.2% +$1.66K 0.23% 103
2022
Q2 		$906K Sell
17,764
-497
-3% -$22.4K 0.23% 106
2022
Q1 		$888K Buy
+18,261
New +$745K 0.2% 109

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FinTrust Capital Advisors's HRMY Position: Q2 2024 in Review

FinTrust Capital Advisors sold out of Harmony Biosciences (HRMY) in Q2 2024, closing a stake of 34 shares — an estimated $1.14K sold.

FinTrust Capital Advisors first reported a position in HRMY in Q1 2022 and held it in 9 quarters. The position peaked at $911K in Q3 2022. 219 funds tracked by Wall St. Rank hold HRMY as of Q2 2024.

  • FinTrust Capital Advisors reported no remaining Harmony Biosciences position as of Q2 2024 after selling out during the quarter.
  • FinTrust Capital Advisors sold 34 Harmony Biosciences shares in Q2 2024, an estimated $1.14K.
  • FinTrust Capital Advisors first reported a position in Harmony Biosciences in Q1 2022 and held it in 9 quarters.
  • FinTrust Capital Advisors's Harmony Biosciences position peaked at $911K in Q3 2022.
  • 219 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2024.

Based on FinTrust Capital Advisors's 13F filing for Q2 2024, filed 24 Jul 2024.